YPYoon Jung Park

Yoon Jung Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoon Jung Park has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Stratified Association of Left Atrial Volume Index and Dynamic Change of Pulmonary Arterial Pressure on Prognosis After Catheter Ablation in Patients With Persistent Atrial Fibrillation

    by Yoon Jung Park, Jiwon Park, Min-Su Jung, Tae-Wan Chung, Hee Jeong Lee, Jongmin Hwang, Hyungseop Kim, Hyoung-Seob Park, In-Cheol Kim

    Park YJ, et al. Korean Circ J. 2027 ;57:e26. https://doi.org/10.4070/kcj.2026.0065

  • Open Access

    Unexplained syncope: what time-to-diagnosis and risk profiles tell us

    by Yoon Jung Park

    Unexplained syncope: what time-to-diagnosis and risk profiles tell us

  • Open Access

    Cardiomyopathy Without Amyloid Deposit in Systemic Light Chain Deposition Disease

    by Bo Eun Park, Se Yong Jang, Yoon Jung Park, Myung Hwan Bae, Jang Hoon Lee, Dong Heon Yang, Hun Sik Park, Yongkeun Cho

    Park BE, et al. Korean Circ J. 2024 Apr;54(4):221-222. https://doi.org/10.4070/kcj.2024.0022


  • Open Access

    Predictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0

    by Hyohun Choi, Myung Hwan Bae, Yoon Jung Park, Hyuk Kyoon Park, Eunkyu Lee, Myeong Seop Kim, Jong Sung Park, Hyeon Jeong Kim, Bo Eun Park, Hong Nyun Kim, et al.

    Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.


  • Open Access

    Impact of Positron Emission Tomography Viability Imaging: Guided Revascularizations on Clinical Outcomes in Patients With Myocardial Scar on Single-Photon Emission Computed Tomography Scans

    by Jong Sung Park, Jang Hoon Lee, Chae Moon Hong, Bo Eun Park, Yoon Jung Park, Hong Nyun Kim, Namkyun Kim, Se Yong Jang, Myung Hwan Bae, Dong Heon Yang, et al.

    Park JS, et al. J Korean Med Sci. 2023 Nov;38:e399. https://doi.org/10.3346/jkms.2023.38.e399


  • Open Access

    Prevalence and Characteristics of Atrial Tachycardia From Noncoronary Aortic Cusp During Atrial Fibrillation Catheter Ablation

    by Myung-Jin Cha, Jun Kim, Yoon Jung Park, Min Soo Cho, Hyoung-Seob Park, Soonil Kwon, Young Soo Lee, Jinhee Ahn, Hyung-Oh Choi, Jong-Sung Park, et al.

    Korean Circulation Journal 대한심장학회지 순환기 Cha MJ, et al. Korean Circ J. 2022 Apr;52:e48. https://doi.org/10.4070/kcj.2021.0388


  • Open Access

    Prognostic impact of chromogranin A in patients with acute heart failure

    by Hong Nyun Kim, Dong Heon Yang, Bo Eun Park, Yoon Jung Park, Hyeon Jeong Kim, Se Yong Jang, Myung Hwan Bae, Jang Hoon Lee, Hun Sik Park, Yongkeun Cho, et al.

    Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.


  • Open Access

    Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery

    by Bo Eun Park, Myung Hwan Bae, Hyeon Jeong Kim, Yoon Jung Park, Hong Nyun Kim, Se Yong Jang, Jang Hoon Lee, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, et al.

    This study aimed to investigate the incidences of and risk factors for perioperative events following anticoagulant discontinuation in patients with non-valvular atrial fibrillation (NVAF) undergoing non-cardiac surgery. A total of 216 consecutive patients who underwent cardiac consultation for suspending perioperative anticoagulants were enrolled. A perioperative event was defined as a composite of thromboembolism and major bleeding. The mean anticoagulant discontinuation duration was 5.7 (±4.2) days and was significantly longer in the warfarin group (p<0.001). Four perioperative thromboembolic (1.85%; three strokes and one systemic embolization) and three major bleeding events (1.39%) were observed. The high CHA2DS2-VASc and HAS-BLED scores and a prolonged preoperative anticoagulant discontinuation duration (4.4±2.1 vs. 2.9±1.8 days; p=0.028) were associated with perioperative events, whereas the anticoagulant type (non-vitamin K antagonist oral anticoagulants or warfarin) was not. The best cut-off levels of the HAS-BLED and CHA2DS2-VASc scores were 3.5 and 2.5, respectively, and the preoperative anticoagulant discontinuation duration for predicting perioperative events was 2.5 days. Significant differences in the perioperative event rates were observed among the four risk groups categorized according to the sum of these values: risk 0, 0%; risk 1, 0%; risk 2, 5.9%; and risk 3, 50.0% (p<0.001). Multivariate logistic regression analysis showed that the HAS-BLED score was an independent predictor for perioperative events. Thromboembolic events and major bleeding are not uncommon during perioperative anticoagulant discontinuation in patients with NVAF, and interrupted anticoagulation strategies are needed to minimize these.


  • Open Access

    Incremental Predictive Value of Plasma Renin Activity as a Prognostic Biomarker in Patients with Heart Failure

    by Bo Eun Park, Dong Heon Yang, Hyeon Jeong Kim, Yoon Jung Park, Hong Nyun Kim, Se Yong Jang, Myung Hwan Bae, Jang Hoon Lee, Hun Sik Park, Yongkeun Cho, et al.

    The association of N-terminal pro-B type natriuretic peptide (NT-proBNP) and plasma renin activity (PRA) for the prognosis of the patients with acute heart failure (HF) has not been fully investigated. This study aimed to determine the association between NT-proBNP and PRA and to investigate the incremental value of PRA to NT-proBNP for predicting long term prognosis in patients with acute HF. Three hundred and ninety-six patients (mean age, 64.7 ± 15.9 years; 46.5% female) presenting with acute HF were enrolled between December 2004 and July 2013. Patients with newly diagnosed HF as well as patients with acute exacerbated chronic HF were included. The prognosis was assessed with the composite event of all-cause mortality and readmission for HF during a 2-year follow-up period. The etiology of HF was ischemic in 116 (29.3%) patients. In a Cox proportional hazards model, log-transformed PRA (hazard ratio [HR], 1.205; P = 0.007) was an independent predictor of the composite outcome of all-cause mortality and readmission for HF in addition to age (HR, 1.032; P = 0.001), white blood cell (WBC) count (HR, 1.103; P < 0.001), and left ventricular ejection fraction (LVEF) (HR, 0.978; P = 0.013). Adding PRA to age, sex, LVEF, and NT-proBNP significantly improved the prediction for the composite outcome of all-cause mortality and readmission for HF, as shown by the net reclassification improvement (0.47; P < 0.001) and integrated discrimination improvement (0.10; P < 0.001). PRA could provide incremental predictive value to NT-proBNP for predicting long term prognosis in patients with acute HF.